Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Identification and characterization of ErbB-3-binding protein-1 as a target for immunotherapy.

Santegoets SJ, Schreurs MW, Reurs AW, Lindenberg JJ, Kueter EW, van den Eertwegh AJ, Hooijberg E, Brandwijk RJ, Hufton SE, Hoogenboom HR, Scheper RJ, Somers VA, de Gruijl TD.

J Immunol. 2007 Aug 1;179(3):2005-12.

2.

MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing.

Held G, Wadle A, Dauth N, Stewart-Jones G, Sturm C, Thiel M, Zwick C, Dieckmann D, Schuler G, Hoogenboom HR, Lévy F, Cerundolo V, Pfreundschuh M, Renner C.

Eur J Immunol. 2007 Jul;37(7):2008-17. Erratum in: Eur J Immunol. 2008 May;38(5):1465-6.

3.

Selecting and screening recombinant antibody libraries.

Hoogenboom HR.

Nat Biotechnol. 2005 Sep;23(9):1105-16. Review.

PMID:
16151404
4.

Oligonucleotide-assisted cleavage and ligation: a novel directional DNA cloning technology to capture cDNAs. Application in the construction of a human immune antibody phage-display library.

Schoonbroodt S, Frans N, DeSouza M, Eren R, Priel S, Brosh N, Ben-Porath J, Zauberman A, Ilan E, Dagan S, Cohen EH, Hoogenboom HR, Ladner RC, Hoet RM.

Nucleic Acids Res. 2005 May 19;33(9):e81.

5.

Optimizing the exogenous antigen loading of monocyte-derived dendritic cells.

Dieckmann D, Schultz ES, Ring B, Chames P, Held G, Hoogenboom HR, Schuler G.

Int Immunol. 2005 May;17(5):621-35. Epub 2005 Apr 11. Retraction in: Int Immunol. 2012 Jun;24(6):401.

PMID:
15824067
6.

Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity.

Hoet RM, Cohen EH, Kent RB, Rookey K, Schoonbroodt S, Hogan S, Rem L, Frans N, Daukandt M, Pieters H, van Hegelsom R, Neer NC, Nastri HG, Rondon IJ, Leeds JA, Hufton SE, Huang L, Kashin I, Devlin M, Kuang G, Steukers M, Viswanathan M, Nixon AE, Sexton DJ, Hoogenboom HR, Ladner RC.

Nat Biotechnol. 2005 Mar;23(3):344-8. Epub 2005 Feb 20.

PMID:
15723048
7.

A major histocompatibility complex-peptide-restricted antibody and t cell receptor molecules recognize their target by distinct binding modes: crystal structure of human leukocyte antigen (HLA)-A1-MAGE-A1 in complex with FAB-HYB3.

Hülsmeyer M, Chames P, Hillig RC, Stanfield RL, Held G, Coulie PG, Alings C, Wille G, Saenger W, Uchanska-Ziegler B, Hoogenboom HR, Ziegler A.

J Biol Chem. 2005 Jan 28;280(4):2972-80. Epub 2004 Nov 10.

8.

Construction and diversification of yeast cell surface displayed libraries by yeast mating: application to the affinity maturation of Fab antibody fragments.

Blaise L, Wehnert A, Steukers MP, van den Beucken T, Hoogenboom HR, Hufton SE.

Gene. 2004 Nov 24;342(2):211-8.

PMID:
15527980
9.

Human antibody fragments specific for the epidermal growth factor receptor selected from large non-immunised phage display libraries.

Souriau C, Rothacker J, Hoogenboom HR, Nice E.

Growth Factors. 2004 Sep;22(3):185-94.

PMID:
15518242
10.

Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.

Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Tai TY, Cohen CJ, Old LJ, Pfreundschuh M, Reiter Y, Hoogenboom HR, Renner C.

Eur J Immunol. 2004 Oct;34(10):2919-29.

11.

Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries.

Mutuberria R, Satijn S, Huijbers A, Van Der Linden E, Lichtenbeld H, Chames P, Arends JW, Hoogenboom HR.

J Immunol Methods. 2004 Apr;287(1-2):31-47.

PMID:
15099754
12.

Affinity maturation of Fab antibody fragments by fluorescent-activated cell sorting of yeast-displayed libraries.

van den Beucken T, Pieters H, Steukers M, van der Vaart M, Ladner RC, Hoogenboom HR, Hufton SE.

FEBS Lett. 2003 Jul 10;546(2-3):288-94.

14.

Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer.

Van Beijnum JR, Moerkerk PT, Gerbers AJ, De Bruïne AP, Arends JW, Hoogenboom HR, Hufton SE.

Int J Cancer. 2002 Sep 10;101(2):118-27.

15.

A panel of candidate tumor antigens in colorectal cancer revealed by the serological selection of a phage displayed cDNA expression library.

Somers VA, Brandwijk RJ, Joosten B, Moerkerk PT, Arends JW, Menheere P, Pieterse WO, Claessen A, Scheper RJ, Hoogenboom HR, Hufton SE.

J Immunol. 2002 Sep 1;169(5):2772-80.

16.

TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity.

Chames P, Willemsen RA, Rojas G, Dieckmann D, Rem L, Schuler G, Bolhuis RL, Hoogenboom HR.

J Immunol. 2002 Jul 15;169(2):1110-8.

17.
19.

A human immunoglobulin G1 antibody originating from an in vitro-selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized.

Henderikx P, Coolen-van Neer N, Jacobs A, van der Linden E, Arends JW, Müllberg J, Hoogenboom HR.

Am J Pathol. 2002 May;160(5):1597-608.

20.

Selection of antibodies against biotinylated antigens.

Chames P, Hoogenboom HR, Henderikx P.

Methods Mol Biol. 2002;178:147-57. Review. No abstract available.

PMID:
11968483
21.

Overview of antibody phage-display technology and its applications.

Hoogenboom HR.

Methods Mol Biol. 2002;178:1-37. Review. No abstract available.

PMID:
11968478
22.

Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault protein.

Scheffer GL, Reurs AW, Jutten B, Beiboer SH, van Amerongen R, Schoester M, Wiemer EA, Hoogenboom HR, Scheper RJ.

Br J Cancer. 2002 Mar 18;86(6):954-62.

23.

A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes.

Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RL, Chames P.

Gene Ther. 2001 Nov;8(21):1601-8.

24.

Evidence for a bias toward intracellular antigens in the local humoral anti-tumor immune response of a colorectal cancer patient revealed by phage display.

Roovers RC, van der Linden E, Zijlema H, de Bruïne A, Arends JW, Hoogenboom HR.

Int J Cancer. 2001 Sep;93(6):832-40.

25.

Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains.

van den Beucken T, van Neer N, Sablon E, Desmet J, Celis L, Hoogenboom HR, Hufton SE.

J Mol Biol. 2001 Jul 13;310(3):591-601.

PMID:
11439026
26.

In vitro characterisation of a monovalent and bivalent form of a fully human anti Ep-CAM phage antibody.

Roovers RC, van der Linden E, de Bruïne AP, Arends JW, Hoogenboom HR.

Cancer Immunol Immunother. 2001 Mar;50(1):51-9.

PMID:
11315510
27.

Identification of colon tumour-associated antigens by phage antibody selections on primary colorectal carcinoma.

Roovers RC, van der Linden E, de Bruïne AP, Arends JW, Hoogenboom HR.

Eur J Cancer. 2001 Mar;37(4):542-9.

PMID:
11267865
28.

Design and application of diabodies, triabodies and tetrabodies for cancer targeting.

Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ.

J Immunol Methods. 2001 Feb 1;248(1-2):47-66. Review.

PMID:
11223068
29.

Natural and designer binding sites made by phage display technology.

Hoogenboom HR, Chames P.

Immunol Today. 2000 Aug;21(8):371-8. Review.

PMID:
10916139
30.

Serological antigen selection of phage displayed colorectal tumour cDNA libraries.

Hufton SE, Moerkerk P, de Bruine A, Arends JW, Hoogenboom HR.

Biochem Soc Trans. 1998 Feb;26(1):S5. No abstract available.

PMID:
10909763
31.

Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning.

Klimka A, Matthey B, Roovers RC, Barth S, Arends JW, Engert A, Hoogenboom HR.

Br J Cancer. 2000 Jul;83(2):252-60.

32.

Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library.

Chames P, Hufton SE, Coulie PG, Uchanska-Ziegler B, Hoogenboom HR.

Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7969-74.

33.

Development and application of cytotoxic T lymphocyte-associated antigen 4 as a protein scaffold for the generation of novel binding ligands.

Hufton SE, van Neer N, van den Beuken T, Desmet J, Sablon E, Hoogenboom HR.

FEBS Lett. 2000 Jun 23;475(3):225-31.

34.

Creating and engineering human antibodies for immunotherapy.

Hoogenboom HR, Henderikx P, de Haard H.

Adv Drug Deliv Rev. 1998 Apr 6;31(1-2):5-31.

PMID:
10837615
35.

Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.

Beiboer SH, Reurs A, Roovers RC, Arends JW, Whitelegg NR, Rees AR, Hoogenboom HR.

J Mol Biol. 2000 Feb 25;296(3):833-49.

PMID:
10677285
36.

Diverting a protein from its cellular location by intracellular antibodies. The case of p21Ras.

Lener M, Horn IR, Cardinale A, Messina S, Nielsen UB, Rybak SM, Hoogenboom HR, Cattaneo A, Biocca S.

Eur J Biochem. 2000 Feb;267(4):1196-205.

37.

Antitransferrin receptor antibody-RNase fusion protein expressed in the mammary gland of transgenic mice.

Newton DL, Pollock D, DiTullio P, Echelard Y, Harvey M, Wilburn B, Williams J, Hoogenboom HR, Raus JC, Meade HM, Rybak SM.

J Immunol Methods. 1999 Dec 10;231(1-2):159-67.

PMID:
10648935
38.

Model systems to study the parameters determining the success of phage antibody selections on complex antigens.

Mutuberria R, Hoogenboom HR, van der Linden E, de Bruïne AP, Roovers RC.

J Immunol Methods. 1999 Dec 10;231(1-2):65-81.

PMID:
10648928
39.

Phage display of cDNA repertoires: the pVI display system and its applications for the selection of immunogenic ligands.

Hufton SE, Moerkerk PT, Meulemans EV, de Bruïne A, Arends JW, Hoogenboom HR.

J Immunol Methods. 1999 Dec 10;231(1-2):39-51.

PMID:
10648926
41.

A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization.

Hufton SE, Moerkerk PT, Brandwijk R, de Bruïne AP, Arends JW, Hoogenboom HR.

FEBS Lett. 1999 Dec 10;463(1-2):77-82.

42.
43.

CD3X anti-nitrophenyl bispecific diabodies: universal immunotherapeutic tools for retargeting T cells to tumors.

Manzke O, Fitzgerald KJ, Holliger P, Klock J, Span M, Fleischmann B, Hescheler J, Qinghua L, Johnson KS, Diehl V, Hoogenboom HR, Bohlen H.

Int J Cancer. 1999 Aug 27;82(5):700-8.

44.

Design and expression of soluble CTLA-4 variable domain as a scaffold for the display of functional polypeptides.

Nuttall SD, Rousch MJ, Irving RA, Hufton SE, Hoogenboom HR, Hudson PJ.

Proteins. 1999 Aug 1;36(2):217-27.

PMID:
10398368
45.

An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.

Klimka A, Barth S, Matthey B, Roovers RC, Lemke H, Hansen H, Arends JW, Diehl V, Hoogenboom HR, Engert A.

Br J Cancer. 1999 Jun;80(8):1214-22.

46.

A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies.

de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruïne AP, Arends JW, Hoogenboom HR.

J Biol Chem. 1999 Jun 25;274(26):18218-30.

47.

Selection-dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library.

Hoogenboom HR, Lutgerink JT, Pelsers MM, Rousch MJ, Coote J, Van Neer N, De Bruïne A, Van Nieuwenhoven FA, Glatz JF, Arends JW.

Eur J Biochem. 1999 Mar;260(3):774-84.

48.

A tandem repeat of MUC1 core protein induces a weak in vitro immune response in human B cells.

Andersson E, Henderikx P, Krambovitis E, Hoogenboom HR, Borrebaeck CA.

Cancer Immunol Immunother. 1999 Jan;47(5):249-56.

PMID:
10022468
49.

Single-chain variable fragments selected on the 57-76 p21Ras neutralising epitope from phage antibody libraries recognise the parental protein.

Persic L, Horn IR, Rybak S, Cattaneo A, Hoogenboom HR, Bradbury A.

FEBS Lett. 1999 Jan 25;443(2):112-6.

50.

Absolute conservation of residue 6 of immunoglobulin heavy chain variable regions of class IIA is required for correct folding.

de Haard HJ, Kazemier B, van der Bent A, Oudshoorn P, Boender P, van Gemen B, Arends JW, Hoogenboom HR.

Protein Eng. 1998 Dec;11(12):1267-76.

PMID:
9930677

Supplemental Content

Loading ...
Support Center